Brief: InMed’S INM-901 Demonstrates Statistically Significant Reduction In Neuroinflammation In Long-Term Preclinical Alzheimer’S Disease Study

InMed Pharmaceuticals

21/01/2025 17:23

Jan 21 (Reuters) - InMed Pharmaceuticals Inc  INM.O :
    * INMED’S INM-901 DEMONSTRATES STATISTICALLY SIGNIFICANT
REDUCTION
IN NEUROINFLAMMATION IN A LONG-TERM PRECLINICAL ALZHEIMER’S
DISEASE STUDY

Source text:  ID:n0001213900-25-004873 
Further company coverage:  INM.O 

 ((Reuters.Briefs@thomsonreuters.com;))